Xevinapant plus avelumab in advanced solid tumours, with a dose expansion in advanced non-small-cell lung cancer: exploratory biomarker, safety and efficacy analyses from an open-label, nonrandomised phase Ib study

Background: Xevinapant, an inhibitor of apoptosis protein (IAP) inhibitor, has shown promising activity in combination with anticancer agents, including radiotherapy, and, in preclinical studies, anti-PD-(L)1 antibodies. This, in part, is due to its ability to restore apoptosis and increase antitumo...

Fuld beskrivelse

Bibliografiske detaljer

Principais autores:	Glenwood Goss, Tudor Ciuleanu, Rodryg Ramlau, Daniel J. Renouf, Quincy Chu, Ewa Kalinka, Piotr Sawrycki, Jonathan Bramson, Brad H. Nelson, Rafael Crabbé, Eric LaCasse, Bryan Lo, Daniela A. Sahlender, Philippa Crompton, Franck Brichory, Luke Piggott, Michael Schenker, Rosalyn Juergens
Format:	Artigo
Sprog:	Inglês
Udgivet:	SAGE Publishing 2025-05-01
Serier:	Therapeutic Advances in Medical Oncology
Online adgang:	https://doi.org/10.1177/17588359251332154
Tags:	Tilføj Tag Ingen Tags, Vær først til at tagge denne postø!